Table 3.
Patients | Age at diagnosis (years) | Gender | Backbone treatment | Target treatment | Target finding | Other treatment | Sides effects | OS (months) |
---|---|---|---|---|---|---|---|---|
1 | 11.93 | M | RTX + temozolomide | Everolimus | m/pmTOR IHC expression | bevacizumab N/V re-irradiation |
Aftosis stomatitis grade II | 26.57 |
2 | 5.06 | F | RTX + N/V | Palovarotene | ACVR1 mutation | Bevacizumab temozolomide re-irradiation |
No | 14.37 |
3 | 8.77 | F | RTX + N/V | Pazopanib | PDGFRA | Bevacizumab temozolomide re-irradiation |
Headache grade II | 18.00 |
4 | 5.04 | F | RTX + N/V | Everolimus | m/pmTOR IHC expression | Bevacizumab temozolomide |
No | 13.97 |
5 | 5.65 | F | RTX + N/V | everolimus | m/pmTOR IHC expression | No (refused) | No | 12.07 |
6 | 5.98 | M | RTX + N/V | everolimus | m/pmTOR IHC expression | Bevacizumab temozolomide re-irradiation |
No | 20.47 |
7 | 6.61 | M | RTX + N/V | everolimus and vemurafenib | m/pmTOR and BRAF IHC expression | Bevacizumab temozolomide re-irradiation |
Aftosis stomatitis grade II | 27.50 |
8 | 7.79 | F | RTX + N/V | everolimus | m/pmTOR IHC expression | Bevacizumab temozolomide re-irradiation |
No | 32.20 |
9 | 6.01 | F | RTX + N/V | palovarotene | ACVR1 mutation | Bevacizumab temozolomide re-irradiation |
Grade III skin toxicity | 20.43 |